CLINICAL_TRIALS
trial_result
· 2017-05-19
Clinical Trial Update: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis [Phase 2]
Summary
Phase 2 pilot trial evaluating imatinib mesylate for treating nephrogenic systemic fibrosis; results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Nephrogenic Systemic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2017-05-19